Home

The preliminary results from a clinical trial assessing a restorative haemodialysis access graft have shown promising early puncturing, patency and safety data. These findings from an ongoing first-in-human study of the Axess graft (Xeltis) are being presented for the first time by trial investigator Matteo Tozzi (University of Insubria, Varese, Italy) today at the Charing Cross Symposium (CX 2022; 26–28 April, London, UK and virtual).

Axess is a synthetic, biocompatible blood vessel, which, overtime, is colonised by the patient’s own tissue following implantation and becomes a living vessel via the process of endogenous tissue restoration.

To date, it has been implanted in 11 end-stage kidney disease patients, with a median follow-up time of 6.5 months, across five European sites as part of the Axess study. Overall, more than 600 dialysis sessions have been enabled in this patient group, with puncturing—or dialysis initiation—starting as early as two weeks after implantation in some patients.

Preliminary data analysis shows “very promising outcomes” on primary endpoints, according to a Xeltis press release. The current data show 100% rates of functional patency and safety, with no aneurysms or infections reported, and “excellent ease-of-use” for surgeons and dialysis nurses, the release adds.

“Our first clinical experience using the Axess device is extremely encouraging. This fully synthetic graft is easy to implant, can be promptly punctured and exhibits an excellent safety profile,” said Tozzi. “Its potential to turn into a longer-lasting natural vessel is an additional benefit and suggests that an optimal solution for dialysis patients may be within our reach.”

“At a time when fistulas are being challenged as a first-line treatment in a number of dialysis patients, the first ever clinical data for Axess are particularly significant, and aligned with its remarkable and unprecedented positive results from preclinical trials, showing its full endothelialisation,” said Frans Moll (University Medical Center Utrecht, Utrecht, The Netherlands), who will present data on preclinical developments with Axess at CX 2022.

“The early outcomes from our Axess trial are very promising, so we have decided to expedite the development of this revolutionary restorative device with an international pivotal trial, starting this year, with the aim to reach patients who need haemodialysis as soon as possible,” said Xeltis CEO Eliane Schutte.

Source VascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Restorative Axess graft demonstrates promising patency and safety in first-in-human study

Chia sẽ qua google bài: Restorative Axess graft demonstrates promising patency and safety in first-in-human study

Chia sẽ qua twitter bài: Restorative Axess graft demonstrates promising patency and safety in first-in-human study

Chia sẽ qua MySpace bài: Restorative Axess graft demonstrates promising patency and safety in first-in-human study

Chia sẽ qua LinkedIn bài: Restorative Axess graft demonstrates promising patency and safety in first-in-human study

Chia sẽ qua stumbleupon bài: Restorative Axess graft demonstrates promising patency and safety in first-in-human study

Chia sẽ qua icio bài: Restorative Axess graft demonstrates promising patency and safety in first-in-human study

Chia sẽ qua digg bài: Restorative Axess graft demonstrates promising patency and safety in first-in-human study

Chia sẽ qua yahoo bài: Restorative Axess graft demonstrates promising patency and safety in first-in-human study

Tin tức liên quan

Vesteck completes first-in-human use of several Suture-Tight devices

Age is just a number: Individual patient data meta-analysis probes safety of CEA in the elderly

Artificial intelligence can predict risk of complications after endovascular aneurysm repair

Bluegrass Vascular announces Journal of Vascular Surgery paper reporting use of Surfacer system

Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.